Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2022-2023.

Angela Sinilaite, Jesse Papenburg
{"title":"Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2022-2023.","authors":"Angela Sinilaite, Jesse Papenburg","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The National Advisory Committee on Immunization (NACI) reviews the evolving evidence on influenza immunization and provides annual recommendations regarding the use of authorized seasonal influenza vaccines to the Public Health Agency of Canada.</p><p><strong>Objective: </strong>To summarize the NACI seasonal influenza vaccine recommendations for 2022-2023 and to highlight new recommendations and supporting evidence.</p><p><strong>Methods: </strong>In the preparation of the Statement on Seasonal Influenza Vaccine for 2022-2023, NACI's Influenza Working Group followed the NACI evidence-based process for developing recommendations. The recommendations were then considered and approved by NACI in light of the available evidence.</p><p><strong>Results: </strong>The following key updates and new recommendations have been made for the 2022-2023 season: 1) updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19) has been incorporated; 2) Supemtek™ recombinant influenza vaccine may be considered for use among the quadrivalent influenza vaccines offered to adults 18 years of age and older for annual influenza immunization; and 3) Flucelvax<sup>®</sup> Quad may be considered among the quadrivalent influenza vaccines offered to adults and children two years of age and older.</p><p><strong>Conclusion: </strong>NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually for all individuals aged six months of age and older who do not have contraindications to the vaccine, with particular focus on people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, and other groups for whom influenza vaccination is particularly recommended.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"48 9","pages":"373-382"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729780/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canada communicable disease report = Releve des maladies transmissibles au Canada","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The National Advisory Committee on Immunization (NACI) reviews the evolving evidence on influenza immunization and provides annual recommendations regarding the use of authorized seasonal influenza vaccines to the Public Health Agency of Canada.

Objective: To summarize the NACI seasonal influenza vaccine recommendations for 2022-2023 and to highlight new recommendations and supporting evidence.

Methods: In the preparation of the Statement on Seasonal Influenza Vaccine for 2022-2023, NACI's Influenza Working Group followed the NACI evidence-based process for developing recommendations. The recommendations were then considered and approved by NACI in light of the available evidence.

Results: The following key updates and new recommendations have been made for the 2022-2023 season: 1) updated information/guidance on influenza vaccination in the context of the coronavirus disease 2019 (COVID-19) has been incorporated; 2) Supemtek™ recombinant influenza vaccine may be considered for use among the quadrivalent influenza vaccines offered to adults 18 years of age and older for annual influenza immunization; and 3) Flucelvax® Quad may be considered among the quadrivalent influenza vaccines offered to adults and children two years of age and older.

Conclusion: NACI continues to recommend that an age-appropriate influenza vaccine should be offered annually for all individuals aged six months of age and older who do not have contraindications to the vaccine, with particular focus on people at high risk of influenza-related complications or hospitalization, people capable of transmitting influenza to those at high risk, and other groups for whom influenza vaccination is particularly recommended.

国家免疫咨询委员会(NACI)2022-2023 年季节性流感疫苗声明摘要。
背景:国家免疫咨询委员会(NACI)审查不断变化的流感免疫证据,并向加拿大公共卫生局提供有关使用授权季节性流感疫苗的年度建议:总结NACI对2022-2023年季节性流感疫苗的建议,并强调新的建议和支持性证据:在编写《2022-2023年季节性流感疫苗声明》的过程中,NACI流感工作组遵循NACI循证程序制定建议。随后,NACI根据现有证据审议并批准了这些建议:针对 2022-2023 年流感季节提出了以下主要更新和新建议:1)纳入了2019年冠状病毒疾病(COVID-19)背景下流感疫苗接种的最新信息/指南;2)Supemtek™重组流感疫苗可考虑用于为18岁及以上成人提供的四价流感疫苗中,作为年度流感免疫接种疫苗;3)Flucelvax® Quad可考虑用于为成人和2岁及以上儿童提供的四价流感疫苗中。结论:NACI 继续建议,应每年为所有年龄在 6 个月及以上且无疫苗禁忌症的人接种适龄流感疫苗,重点关注流感相关并发症或住院治疗的高危人群、可能将流感传染给高危人群的人群,以及其他特别建议接种流感疫苗的人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信